Published in Cancer Res on June 15, 1999
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res (2005) 3.41
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell (2009) 2.10
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci U S A (2002) 1.89
Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol (2004) 1.77
MYC and Breast Cancer. Genes Cancer (2010) 1.66
Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J Exp Med (2000) 1.61
Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res (2011) 1.54
MYC in breast tumor progression. Expert Rev Anticancer Ther (2008) 1.49
Differential gene regulation by the SRC family of coactivators. Genes Dev (2004) 1.41
Characterization of transcriptome dynamics during watermelon fruit development: sequencing, assembly, annotation and gene expression profiles. BMC Genomics (2011) 1.28
Pseudomonas stutzeri nitrite reductase gene abundance in environmental samples measured by real-time PCR. Appl Environ Microbiol (2001) 1.27
Key signaling nodes in mammary gland development and cancer: β-catenin. Breast Cancer Res (2010) 1.24
Gene expression in developing watermelon fruit. BMC Genomics (2008) 1.21
Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol (2011) 1.21
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol (2011) 1.21
Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer (2004) 1.19
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer (2003) 1.19
Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc Natl Acad Sci U S A (2011) 1.16
IL-6 gene amplification and expression in human glioblastomas. Br J Cancer (2001) 1.14
Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. Br J Cancer (2004) 1.11
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol (2002) 1.11
The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res (2011) 1.07
Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer (2002) 1.06
Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer (2004) 1.06
Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Mol Cancer (2006) 1.04
Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC. Mol Cell (2011) 1.03
Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis. Proc Natl Acad Sci U S A (2013) 1.02
A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer (2011) 1.02
Comparative expression of hexose transporters (SGLT1, GLUT1, GLUT2 and GLUT5) throughout the mouse gastrointestinal tract. Histochem Cell Biol (2011) 0.99
Hypoxia inducible factor 1alpha gene (HIF-1alpha) splice variants: potential prognostic biomarkers in breast cancer. BMC Med (2010) 0.97
Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas. Am J Pathol (2000) 0.96
Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast. Breast Cancer Res (2003) 0.88
C-myc as a predictive marker for chemotherapy in metastatic breast cancer. Clin Exp Med (2011) 0.87
Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer. Br J Cancer (2001) 0.87
Identification of a three-gene expression signature of poor-prognosis breast carcinoma. Mol Cancer (2004) 0.86
Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain. J Bone Miner Metab (2005) 0.85
EGCG inhibits proliferation, invasiveness and tumor growth by up-regulation of adhesion molecules, suppression of gelatinases activity, and induction of apoptosis in nasopharyngeal carcinoma cells. Int J Mol Sci (2015) 0.85
Expression of a novel lacrimal gland gene lacritin in human breast tissues. J Cancer Res Clin Oncol (2003) 0.83
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. Clin Cancer Res (2013) 0.82
Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells. PLoS One (2011) 0.81
DREAM mediated regulation of GCM1 in the human placental trophoblast. PLoS One (2013) 0.80
Effective Alu repeat based RT-Qpcr normalization in cancer cell perturbation experiments. PLoS One (2013) 0.80
Effect of Neem Leaf Extract (Azadirachta indica) on c-Myc Oncogene Expression in 4T1 Breast Cancer Cells of BALB/c Mice. Cell J (2012) 0.80
Passage-affected competitive regulation of osteoprotegerin synthesis and the receptor activator of nuclear factor-kappaB ligand mRNA expression in normal human osteoblasts stimulated by the application of cyclic tensile strain. J Bone Miner Metab (2009) 0.79
Expression profiles of fibrinolytic components in nasal mucosa. Histochem Cell Biol (2004) 0.77
The c-MYC protooncogene expression in cholesteatoma. Biomed Res Int (2014) 0.76
Mapping of Mcs30, a new mammary carcinoma susceptibility quantitative trait locus (QTL30) on rat chromosome 12: identification of fry as a candidate Mcs gene. PLoS One (2013) 0.75
FOXR2 Interacts with MYC to Promote Its Transcriptional Activities and Tumorigenesis. Cell Rep (2016) 0.75
The role of β-catenin in the initiation and metastasis of TA2 mice spontaneous breast cancer. J Cancer (2017) 0.75
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet (1992) 3.11
Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. N Engl J Med (1994) 2.94
Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci U S A (1986) 2.66
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet (1998) 2.59
Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst (1994) 2.58
Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer (1998) 2.52
High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology (2001) 2.41
Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR. J Clin Microbiol (1995) 2.28
Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science (1987) 2.17
Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer (1998) 2.09
Presence of two members of c-erbA receptor gene family (c-erbA beta and c-erbA2) in smallest region of somatic homozygosity on chromosome 3p21-p25 in human breast carcinoma. J Natl Cancer Inst (1989) 2.09
Detection of Toxoplasma gondii by competitive DNA amplification of bronchoalveolar lavage samples. J Infect Dis (1993) 2.04
Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics (1995) 1.96
Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer (2006) 1.96
Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology (1999) 1.94
Genetic alterations in breast cancer. Genes Chromosomes Cancer (1995) 1.86
Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res (1998) 1.80
A refined molecular taxonomy of breast cancer. Oncogene (2011) 1.78
Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum (1999) 1.77
Presence of an allelic EcoRI restriction fragment of the c-mos locus in leukocyte and tumor cell DNAs of breast cancer patients. Proc Natl Acad Sci U S A (1985) 1.77
Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem (1999) 1.74
Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res (2001) 1.72
Somatic mutations and human breast cancer. A status report. Cancer (1992) 1.69
Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet (2003) 1.62
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. Oncogene (1995) 1.58
Real-time PCR as a new tool for quantifying Leishmania infantum in liver in infected mice. Clin Diagn Lab Immunol (2001) 1.58
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut (2009) 1.56
Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia (2000) 1.55
VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer (2000) 1.54
Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res (2000) 1.53
High frequency of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients. J Natl Cancer Inst (1986) 1.52
Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. Cancer Res (1986) 1.52
Somatic allelic deletion of nm23 in human cancer. Cancer Res (1991) 1.50
A 5' splice-region G----C mutation in exon 1 of the human beta-globin gene inhibits pre-mRNA splicing: a mechanism for beta+-thalassemia. Proc Natl Acad Sci U S A (1989) 1.48
TaqMan PCR-based gene dosage assay for predictive testing in individuals from a cancer family with INK4 locus haploinsufficiency. Clin Chem (1999) 1.48
Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res (2001) 1.45
PCR enzyme-linked immunosorbent assay for diagnosis of leishmaniasis in human immunodeficiency virus-infected patients. J Clin Microbiol (1996) 1.42
Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas. Cancer Res (1989) 1.41
Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. EMBO J (1991) 1.40
Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer (2000) 1.39
Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology (1998) 1.37
Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet (2008) 1.36
Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res (1993) 1.33
Sex differences in mutational rate and mutational mechanism in the NF1 gene in neurofibromatosis type 1 patients. Hum Genet (1996) 1.31
Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene (2001) 1.29
SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet (2009) 1.28
Characterization of human villous and extravillous trophoblasts isolated from first trimester placenta. Lab Invest (2001) 1.27
Mutations in the catalytic domain of human coagulation factor IX: rapid characterization by direct genomic sequencing of DNA fragments displaying an altered melting behavior. Genomics (1989) 1.26
Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology (1997) 1.24
Development of two real-time quantitative TaqMan PCR assays to detect circulating Aspergillus fumigatus DNA in serum. J Microbiol Methods (2001) 1.24
Haemophilia B due to a de novo insertion of a human-specific Alu subfamily member within the coding region of the factor IX gene. Eur J Hum Genet (1993) 1.24
(C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci U S A (1994) 1.24
Hemoglobin S Antilles: a variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes. Proc Natl Acad Sci U S A (1986) 1.23
Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Cancer Res (1996) 1.22
PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene (1998) 1.20
Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer. Clin Cancer Res (1996) 1.20
Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein. Oncogene (2009) 1.15
Loss of heterozygosity on chromosomes 17 and 18 in breast carcinoma: two additional regions identified. Proc Natl Acad Sci U S A (1990) 1.15
Deletion mapping of chromosomal region 1p32-pter in primary breast cancer. Genes Chromosomes Cancer (1999) 1.15
Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology (1999) 1.14
Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene. Carcinogenesis (2001) 1.14
Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. Br J Cancer (1996) 1.12
Defect of villous cytotrophoblast differentiation into syncytiotrophoblast in Down's syndrome. J Clin Endocrinol Metab (2000) 1.12
Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res (1998) 1.12
Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut (2003) 1.11